Olema Pharmaceuticals Inc (OLMA) Stock Price, Quote & News

Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivota...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 651 3316

Website: olema.com

Address:

780 Brannan Street, San Francisco, United States

VoidVortex Feb. 4 at 10:04 AM

$OLMA biotech, ophthalmology focus

0 · Reply

Zaksab Feb. 2 at 6:04 PM

$OLMA possibly bid spec increases

0 · Reply

Keystone1 Feb. 2 at 4:15 PM

$OLMA Recovering nicely from today’s 23$ low. It would be incredible to see a green close!

0 · Reply

jockburke Jan. 31 at 5:38 PM

$OLMA

1 · Reply

Zaksab Jan. 30 at 10:19 PM

$OLMA odd

0 · Reply

Dr_Stoxx Jan. 30 at 4:31 PM

There are a few bios that look okay here. $OLMA is one of them

0 · Reply

OX50 Jan. 29 at 9:10 PM

$OLMA $NVO $CORT $NVAX

1 · Reply

AbovetheGreenLine Jan. 29 at 8:02 PM

Swing Trade Buy on the Close for Olema Pharma $OLMA, but it is already up 7% (Caution). https://abovethegreenline.com/wp-content/uploads/20

0 · Reply

topstockalerts Jan. 29 at 3:48 PM

$OLMA Starting to wake up as volume increases. Buyers are getting more aggressive at these levels. Worth keeping this on radar.

0 · Reply

Icemanrush16 Jan. 29 at 3:16 PM

$OLMA merci

0 · Reply

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 30, 2026, 4:01 PM EST - 4 days ago

Olema Oncology Announces Departure of Chief Operating and Financial Officer

Jan 22, 2026, 10:26 AM EST - 12 days ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 15, 2026, 12:05 PM EST - 19 days ago

Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 5, 2026, 7:00 AM EST - 4 weeks ago

Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 24, 2025, 9:00 AM EST - 5 weeks ago

Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal

Nov 21, 2025, 4:30 PM EST - 2 months ago

Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Nov 20, 2025, 4:01 PM EST - 2 months ago

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Nov 18, 2025, 4:51 PM EST - 2 months ago

Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 18, 2025, 4:21 PM EST - 2 months ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN JNJ LLY MDT MRK NVO PFE

Nov 18, 2025, 12:01 PM EST - 2 months ago

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock

Nov 18, 2025, 10:21 AM EST - 2 months ago

OLMA stock: could today's 197% surge be just the beginning?

Nov 18, 2025, 9:56 AM EST - 2 months ago

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why

Nov 10, 2025, 7:00 AM EST - 3 months ago

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Nov 3, 2025, 4:30 PM EST - 3 months ago

Olema Oncology to Participate in Upcoming Investor Conferences

Oct 30, 2025, 4:30 PM EDT - 3 months ago

Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025

Oct 30, 2025, 3:25 PM EDT - 3 months ago

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Oct 18, 2025, 3:00 AM EDT - 3 months ago

Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025

Sep 2, 2025, 7:00 AM EDT - 5 months ago

Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer

PFE

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

May 28, 2025, 7:00 AM EDT - 9 months ago

Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting

May 13, 2025, 4:01 PM EDT - 9 months ago

Olema Oncology Reports First Quarter 2025 Financial and Operating Results

Apr 25, 2025, 1:00 PM EDT - 10 months ago

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

Apr 8, 2025, 4:25 PM EDT - 10 months ago

Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market

Mar 25, 2025, 4:31 PM EDT - 11 months ago

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Mar 18, 2025, 4:01 PM EDT - 11 months ago

Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 7:00 AM EST - 1 year ago

Olema Oncology Appoints Shawnte M. Mitchell, J.D.

Jan 2, 2025, 7:00 AM EST - 1 year ago

Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:46 AM EST - 1 year ago

Top 3 Health Care Stocks That May Explode In Q4

SLN

Dec 10, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium

Dec 9, 2024, 7:00 AM EST - 1 year ago

Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor

Nov 25, 2024, 5:30 PM EST - 1 year ago

Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium

Nov 12, 2024, 4:01 PM EST - 1 year ago

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 6, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 28, 2024, 7:03 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in June

May 15, 2024, 7:01 AM EDT - 1 year ago

Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress

May 8, 2024, 4:02 PM EDT - 1 year ago

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress

May 1, 2024, 7:02 AM EDT - 1 year ago

Olema Oncology to Participate in Upcoming Investor Conferences in May

Apr 8, 2024, 4:30 PM EDT - 1 year ago

Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference

Mar 11, 2024, 4:03 PM EDT - 2 years ago

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 7:03 AM EST - 2 years ago

Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Jan 8, 2024, 8:12 AM EST - 2 years ago

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Jan 3, 2024, 8:29 AM EST - 2 years ago

Olema Pharmaceuticals: Oral SERD Developer With Interesting Data

Jan 2, 2024, 4:01 PM EST - 2 years ago

Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023, 12:27 PM EST - 2 years ago

Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies

Nov 28, 2023, 5:10 PM EST - 2 years ago

Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

VoidVortex Feb. 4 at 10:04 AM

$OLMA biotech, ophthalmology focus

0 · Reply

Zaksab Feb. 2 at 6:04 PM

$OLMA possibly bid spec increases

0 · Reply

Keystone1 Feb. 2 at 4:15 PM

$OLMA Recovering nicely from today’s 23$ low. It would be incredible to see a green close!

0 · Reply

jockburke Jan. 31 at 5:38 PM

$OLMA

1 · Reply

Zaksab Jan. 30 at 10:19 PM

$OLMA odd

0 · Reply

Dr_Stoxx Jan. 30 at 4:31 PM

There are a few bios that look okay here. $OLMA is one of them

0 · Reply

OX50 Jan. 29 at 9:10 PM

$OLMA $NVO $CORT $NVAX

1 · Reply

AbovetheGreenLine Jan. 29 at 8:02 PM

Swing Trade Buy on the Close for Olema Pharma $OLMA, but it is already up 7% (Caution). https://abovethegreenline.com/wp-content/uploads/20

0 · Reply

topstockalerts Jan. 29 at 3:48 PM

$OLMA Starting to wake up as volume increases. Buyers are getting more aggressive at these levels. Worth keeping this on radar.

0 · Reply

Icemanrush16 Jan. 29 at 3:16 PM

$OLMA merci

0 · Reply

Icemanrush16 Jan. 28 at 8:38 PM

$OLMA $NVO $CORT $NVAX pharma getting hit hard today - does not change the fundamentals of stocks. Pullbacks are part of the game. ✌🏼

0 · Reply

Icemanrush16 Jan. 28 at 7:30 PM

$OLMA in

0 · Reply

SuperGreenToday Jan. 24 at 4:10 PM

$OLMA Share Price: $25.21 Contract Selected: Jul 17, 2026 $25 Calls Buy Zone: $5.87 – $7.25 Target Zone: $10.11 – $12.36 Potential Upside: 63% ROI Time to Expiration: 173 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BillionerOfKing Jan. 20 at 3:51 AM

$OLMA Current Stock Price: $27.14 Contracts to trade: $25 OLMA Feb 20 2026 Call Entry: $3.30 Exit: $6.52 ROI: 98% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Timetoflytothemoon Jan. 15 at 1:08 PM

$IXHL award winner $ASBP $OLMA $OCGN

0 · Reply

Keystone1 Jan. 14 at 4:22 PM

$OLMA Jumping nicely today, any news driving it???

0 · Reply

Keystone1 Jan. 12 at 4:32 PM

$OLMA Moving up nicely, acting bullish! Hopefully back over 30 soon.

0 · Reply

AbovetheGreenLine Jan. 12 at 2:47 PM

Olema Pharma $OLMA is up 13 %. Sell if it trades at $28 today. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zp

0 · Reply

JFais Jan. 10 at 1:10 PM

$OLMA- thanks for the reminder to revisit @lfholt, has popped up in scans several times (caveat= competitive landscape evolving VERY quickly)

0 · Reply

Intuitive_ Jan. 9 at 11:47 PM

$OLMA bullish indicators for a good swing trade, SMA 50 above SMA 200, price above SMA 200; RSI below 65, MACD recently crossed / about to cross positive. Watch this stock over the next 1-3 months it will go up anywhere from 30-100%. Follow me for more of the best inicator based trade ideas!

0 · Reply

Keystone1 Jan. 9 at 7:41 PM

$OLMA Acting very bullish today! Something in the works???

1 · Reply

AbovetheGreenLine Jan. 6 at 8:01 PM

Swing Trade Buy on the Close for Olema Pharma. $OLMA. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/3zBE

0 · Reply

Market Cap	1.77B
Revenue (ttm)	0.00
Net Income (ttm)	-129.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.01

Volume	1,470,100
Avg Vol	2,376,264
Day's Range	N/A - N/A
Shares Out	68.66M
Stochastic %K	64%
Beta	1.92
Analysts	Strong Sell
Price Target	$45.90